ID   RCC-26
AC   CVCL_VQ70
SY   RCC26
DR   Lonza; 754
DR   Wikidata; Q98128861
RX   PubMed=8409397;
RX   PubMed=11175312;
RX   PubMed=11809699;
RX   PubMed=15755994;
RX   PubMed=15997395;
RX   PubMed=16045799;
RX   PubMed=16261161;
CC   HLA typing: A*02:01,33:03; B*41:01,51:01; C*15:02,17:01 (PubMed=11175312).
CC   Derived from site: In situ; Kidney; UBERON=UBERON_0002113.
CC   Cell type: Epithelial cell of kidney; CL=CL_0002518.
DI   NCIt; C4033; Clear cell renal cell carcinoma
DI   ORDO; Orphanet_319276; Clear cell renal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C3HP ! LCL-26
CA   Cancer cell line
DT   Created: 13-11-18; Last updated: 05-10-23; Version: 7
//
RX   PubMed=8409397; DOI=10.4049/jimmunol.151.8.4209;
RA   Schendel D.J., Gansbacher B., Oberneder R., Kriegmair M.,
RA   Hofstetter A., Riethmuller G., Segurado O.G.;
RT   "Tumor-specific lysis of human renal cell carcinomas by
RT   tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of
RT   autologous and allogeneic tumor lines.";
RL   J. Immunol. 151:4209-4220(1993).
//
RX   PubMed=11175312; DOI=10.1038/sj.gt.3301349;
RA   Schendel D.J., Frankenberger B., Jantzer P., Cayeux S., Noessner E.,
RA   Willimsky G., Maget B., Pohla H., Blankenstein T.;
RT   "Expression of B7.1 (CD80) in a renal cell carcinoma line allows
RT   expansion of tumor-associated cytotoxic T lymphocytes in the presence
RT   of an alloresponse.";
RL   Gene Ther. 7:2007-2014(2000).
//
RX   PubMed=11809699;
RA   Falk C.S., Noessner E., Weiss E.H., Schendel D.J.;
RT   "Retaliation against tumor cells showing aberrant HLA expression using
RT   lymphokine activated killer-derived T cells.";
RL   Cancer Res. 62:480-487(2002).
//
RX   PubMed=15755994; DOI=10.1158/1078-0432.CCR-04-1883;
RA   Frankenberger B., Pohla H., Noessner E., Willimsky G., Papier B.,
RA   Pezzutto A., Kopp J., Oberneder R., Blankenstein T., Schendel D.J.;
RT   "Influence of CD80, interleukin-2, and interleukin-7 expression in
RT   human renal cell carcinoma on the expansion, function, and survival of
RT   tumor-specific CTLs.";
RL   Clin. Cancer Res. 11:1733-1742(2005).
//
RX   PubMed=15997395; DOI=10.1007/s00345-005-0505-5;
RA   Frankenberger B., Regn S., Geiger C., Noessner E., Falk C.S.,
RA   Pohla H., Javorovic M., Silberzahn T., Wilde S., Buchner A.,
RA   Siebels M., Oberneder R., Willimsky G., Pezzutto A., Blankenstein T.,
RA   Schendel D.J.;
RT   "Cell-based vaccines for renal cell carcinoma: genetically-engineered
RT   tumor cells and monocyte-derived dendritic cells.";
RL   World J. Urol. 23:166-174(2005).
//
RX   PubMed=16045799; DOI=10.1186/1479-5876-3-29; PMCID=PMC1188079;
RA   Geiger C., Regn S., Weinzierl A., Noessner E., Schendel D.J.;
RT   "A generic RNA-pulsed dendritic cell vaccine strategy for renal cell
RT   carcinoma.";
RL   J. Transl. Med. 3:29.1-29.15(2005).
//
RX   PubMed=16261161; DOI=10.1038/sj.onc.1209188;
RA   Djafarzadeh R., Noessner E., Engelmann H., Schendel D.J.,
RA   Notohamiprodjo M., von Luettichau I., Nelson P.J.;
RT   "GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive
RT   to FAS-meditated killing.";
RL   Oncogene 25:1496-1508(2006).
//